Symphytum / Smeerwortel

In de naam van... Smeerwortel

Namen van vooral medicinale planten hebben soms een geschiedenis van duizenden jaren achter zich. Een naam zorgt ervoor dat we weten over welke plant generaties kruidkundigen voor ons schreven, maar de naam zelf zegt ook veel over de gebruikswaarde, de groeiplaats en het uiterlijk van de plant.

Smeerwortel / Symphytum officinale een inheemse vaste plant uit de familie van de Ruwbladigen. Aai maar eens over het blad, dan zul je direct voelen dat deze plant ruw bladig is. De smeerwortel zelf heeft zijn naam ook niet gestolen. Het is de wortel die medicinaal het meest gebruikt word en dan vooral ook als smeersel (zalf), om de gewrichten te smeren en omdat er zoveel smeer (slijmstof) in de plant aanwezig is. Dat de plant smerig zou zijn, gaat mij iets te ver als naamverklaring. Ook de officiële Latijnse naam Symphytum verwijst naar zijn werking op het beenderstelsel ter genezing van botbreuken. Sumphuton betekent samengroeien. Ook in oude kruidenboeken zoals het Antidotarium Nicolai wordt hij Simfitum of Walwortel genoemd. Bij genezing van botbreuken ontstaat er een verdikking op de plaats waar het bot zich herstelt (callusvorming), een soor wal, verhoging dus. Mogelijk vandaar Waelwortel al zou waelen ook van kenteren kunnen komen, of van het Oudhoogduits wallen, wellen is helen, of zelfs waal als poel of plas. Genoeg mogelijkheden dus maar allemaal betekenissen die iets vertellen over de werking of de groeiplaats van de plant..

Een van de oudste geschriften waar de Smeerwortel vernoemd word is de Pseudo-Apuleius (4de eeuw ) en wel onder de naam Confirma, ook hier weer een verwijzing naar vastmaken, bevestigen, confirmeren. Bij Hildegard van Bingen lezen we ‘Consolida’, een naam die nu ook nog wel eens gebruikt word, de Franse naam is Consoude en de Italiaanse Consolida maggiore, van souder, lassen of aan mekaar maken. Ook het Duitse ‘Beinwell’ en het Engelse ‘Boneset’ verwijzen naar zijn genezende werking bij botbreuken.

De naam Waelwortel en vele andere namen vinden we ook bij Dodonaeus, die schrijft in zijn Cruydt-boeck: 'Dit cruyt heet in Griecx Symphyton, ende Symphyton mega. In Latijn Symphytum magnum en Solidago. In die Apoteke Consolida maior. In Hoochduytsch Walwurtz/ Schmerwurtz/ Schwartwurtz/ Schantzwurtz/ Beinwellen. In Neerduytsch Waelwortel. In Franchois Consyre'.

En over de medicinale werking heeft hij zoals gewoonlijk een mooi verhaal in petto: 'Die selve wortele ghestooten heylt ende gheneest alle versche wonden gelijck een plaester daer op gheleyt/ ende es soo seer heylsaem dat zy met eenen huspot oft andere stucken van vleesch ghesoden/ die stucken al tsamen aen een doet wassen'.

Ik heb het nog niet geprobeerd om brokken vlees in een hutsepot terug aan mekaar te laten groeien, maar het is wel een beetje waar, omdat de slijmstoffen in deze plant een waterbindend effect kunnen hebben in saus of soep. Veel van die straffe verhalen waren volgens mij toch vooral bedoeld om de werking van de plant beter te onthouden. Dus als geheugensteuntje.

Overzicht andere volksnamen

Enkele andere Nederlandse volksnamen: Ezelsoor, Heelbeen, Heelwortel, Keelwortel, Schuurwortel, Spekwortel

Engelse benamingen: Boneset, Bruisewort, Knit Back, Knit Bone, Slippery Root, Black Wort

Duits: Beinheil, Beinwurz, Eselohrwurzel, Hasenlaub, Soldatenwurz, Wallwurz,

Frans: Consoude officinale, langue de vache, Herbe à la coupure, Herbe aux charpentiers

Comfrey and PAs

Comfrey (Symphytum spp.), long one of the most popular herbs in European folk medicine, has become increasingly controversial because of reports that it is toxic to the liver, and perhaps carcinogenic. At issue is a class of chemicals called pyrrolizidine alkaloids (PAs). Alkaloids of this type are responsible for the toxicity of such poisonous plants as Heliotropium, Crotalaria, and Senecio. They have caused substantial losses of grazing livestock, and some human poisonings as well. The alkaloids damage the veins within the liver, causing a condition known as hepatic veno-occlusive disease (HVOD). Different PAs have different toxicities, further complicaring matters.

Comfrey has been known since at least the 1960s to contain PAs, which in sufficient doses, have caused liver damage and minors in lab animals. The risk to humans is a matter of serious debate, while international government regulation is showing a trend toward eliminating the casual consumption of comfrey. Comfrey root is much higher in alkaloids than leaf, and young leaves contain more than older leaves. The U.S. FDA has sampled a variety of comfrey products for analysis, and will ultimately make a decision about how such products are to be regulated. Australia has banned comfrey, while Canada has proposed a ban on its use in food and restricted its medicinal use. Germany and New Zealand have also restricted its use. This article details the toxicity of the comfrey alkaloids and the latest Canadian regulatory activity -- RMc.

The first Canadian action was taken in 1982, when the Health Protection Branch of Health and Welfare Canada introduced an amendment to Canada's Food and Drug Regulations which prohibits the sale, for medicinal purposes, of any products containing echimidine (Canada Gazette, 30 March 1988). Echimidine, considered to be the most toxic of comfrey PAs (Brauchli-Theotokis 1987), is not found in common comfrey (Symphytum officinale L.). However, it is present in prickly comfrey (S. asperum Lepechin) and its hybrids with S. officinale (Huizing, Gadella, and Kliphuis 1982), including Russian comfrey (S. x uplandicum Nyman), which is the most commonly encountered commercial comfrey in Britain (Clapham, Tutin and Warburg 1962). The intent of this legislation is to have more careful attention paid to identification of botanical species by the herbal industry, and to alert the Canadian public to the potential danger of PA consumption. There was no intent to underestimate the relative potent ial danger of echimidine-free S. officinale. Both root and leaf of "S. officinale" have been shown to be carcinogenic in rats (Hirono et al. 1978), though here again there is Species confusion because the authors equate common comfrey and Russian comfrey! Also, like echimidine (Mattocks 1986), most of the constituent PAs of S. officinale have responded positively in in vivo mutagenicity tests using fruit fly (Drosophila) cells (Würgler and Vogel 1986).

Examination of comfrey products available in Canada (Awang et al. 1988) revealed that none was designated or labelled as Russian comfrey or by its Latin binomial, Symphytum x uplandicum. Products were labelled as either simply "comfrey" or Symphytum officinale (common comfrey). However, just about half (6) of all products analyzed (13) were found to contain echimidine,and must therefore have derived from S. asperum or a hybrid of that species, probably S. x uplandicum. Three of the six echimidine-containing products were specifically labelled as Symphytum officinale. The PA composition of one root product was almost exclusively echimidine -- better than 85% by HPLC!

Health and Welfare Canada has for many years refused to register cormfrey root products for any medicinal application, in recognition of the much greater risk presented by root material as compared to leaf. Comfrey root has been consistently observed to contain roughly ten times the concentration of PA found in leaves (Mattocks 1986, Roitman 1981). Manufacturers have been advised that the inclusion of comfrey root in herbal preparations is no longer acceptable.

Four cases of human poisoning by comfrey have now been published. The first case (Ridker et al. 1985) involved a 49-year-old woman in Boston diagnosed as suffering from veno-occlusive disease (VOD), characteristic of PA intoxication. Chronic ingestion of a comfrey root preparation was implicated and gas chromatographic/mass spectrometric (GC/MS) analysis of the suspected product supported its identity as S. officinale since no echimidine was detected (Huxtable, Lüthy, and Zweifel 1986). The second case, reported in the British Medical Journal (Weston et al. 1987), was claimed to be "the first to result from a native British plant." However, while S. officinale is native to Britain, S. x uplandicum (earlier noted to be the most common commercial species in the UK) results from hybridization of S. officinale with S. asperum from the Caucasus -- hence its common name, "Russian comfrey" (Hills 1977). It is not clear whether this case truly involved S. officinale, since neither confirmation of botanical identity nor analysis of PA was performed on the material implicated in their case of poisoning. A third case (Bach, Thung and Schaffner 1989) described VOD in a 47-year-old woman who was consuming as many as 10 cups of comfrey tea per day in addition to taking comfrey-pepsin tablets (species unidentified) "by the handful" for more than a year. The fourth and last case (Yeong et al. 1990)reported the death from liver failure of a 23-year-old man in New Zealand. The subject had been ingesting four to five fresh young comfrey leaves daily (species undetermined).

A widespread lack of attention to proper botanical identification of Symphytum species by herbal investigators from different disciplines has led to much confusion and perpetuated serious errors in the literature. The British Medical Journal, for example, is very misleading in stating that at least nine PAs are present in the leaves and roots of S. officinale. The reference cited (Smith and Culvenor 1981),in fact, lists the tabulated results of eight investigations covering, variously, wholeplant, root, and herb, from four different geographic locations. Perhaps the most damaging account in this area is the publication from Japan which reports on the constituent of "Symphytum officinale Linn." (Furuya and Araki 1968). The authors' statement that this species "is called comfrey or Russian Comfrey" is responsible for the widespread -- and fallacious -- claim that that species contains echimidine. It is quite obvious that these workers were dealing with a S. asperum hybrid. Also wi dely circulated but never confirmed is the notion that Symphytum spp. may contain the noxious diester PA, lasiocarpine -- following a USSR report (Man'ko et al. 1970), which based identification of the alkaloid solely on paper chromatography! (See: Awang 1987 for an evaluation of the evidence).

The acetyl diesters, 7-acetylintermedine and 7-acetyllycopsamine, have been found to be the predominant PA in S. officinale root, associated with lesser amounts of their uncetylated parents, and symphytine (Branchli et al 1982).

A recent examination of commercial comfrey root sold in the United States revealed a PA profile indicative of S. officinale (Vollmer et al. 1987).

An excellent investigation of the PA constituents of S. x uplandicum (Russian comfrey) grown in Australia was published by C. C. J. Culvenor and his colleagues at the Commonwealth Scientific and Industrial Research Organization (CSIRO) in 1980 (Culvenor et al. 1980). Eight PAs, including echimidine and symphytine, the two most toxic comfrey alkaloids, were identified. These two PAs are very similar in acute toxicity (as measured by LD(50) values). One report assigned values of 200 and 300 mg/kg respectively (Hirono et al. 1978). A later report (Brauchli-Theotokis 1987)lidts comparable values of 125-200 (echimidine) and 220-300 (symphytine)mg/kg. Both studies used intraperitoneal injection in rats.

The Health Risks

Over 200 PAs have been found in plants, mainly from the borage family -- Boraginaceae (eg. Symphytum, Heliotropium); the aster family -- Compositae/Asteraceae (eg. Senecio); and the pea family -- Leguminosae/Fabaceae (eg. Crotalaria) (Cheeke 1988) and an estimated 3% of the world's flowering plants may contain them (Culvenor 1980). The most acutely toxic PAs include those in senecio and crotalaria.(1) The kinds of PAs found in comfrey are generally less toxic (Mattocks 1986). However, PAs of the type found in comfrey must also be regarded as having the potential for liver damage due to chronic toxicity at surprisingly low levels. Humans are believed to be more susceptible to PA poisoning than are the common laboratory animals (Culvenor, personal communication 1987).

Since toxicity of PA seems to result from highly reactive compounds formed during PA metabolism in the liver, external use of comfrey is considered relatively safe (Mattocks 1968).(2) Also, since as much as 90% of total plant alkaloids may be in the form of highly water-soluble N-oxides (Roitman 1983), boiling comfrey leaf as a vegetable should reduce toxicity, because most of the alkaloids would be discarded with the water. These N-oxides are metabolized differently by the liver, with less toxic by-products than the free alkaloids (Mattocks 1971).(3) However, when administered orally to rats and sheep, N-oxides are converted in the gut and rumen, respectively, to their parent alkaloids, with the resulting higher toxicity. Also, human cancer patients under intravenous treatment with indicine-N-oxide experience liver damage, likely due to the free alkaloid, which has been detected in the blood (Ames, as cited in Culvenor 1980).

While debate continues on the safety of comfrey, current evidence indicates that commercial comfrey preparations are not always derived from S. officinale. Uncertainties in the marketplace are compounded by errors in the scientific literature, further complicating safety evaluation. The presence of echimidine (likely the most toxic alkaloid) in commercial products has led the Canadian government to propose a general ban on comfrey. In the U.S. the American Herbal Products Association and the FDA are both reviewing the literature on comfrey to determine what action may be appropriate regarding marketing of comfrey products.

References

Awang, D. V. C. 1987. Comfrey. Can. Pharm. J. 125:100-104.

Awang, D. V. C., J. Fillion, M. Girard, and D. Kindack. 1988. In preparation. Presented in part to International Congress on Natural Products Research, Park City, Utah, 17-21 July 1988.

Bach, N., S. N. Thung & F.Schaffner. 1989. Comfrey Herb Tea-Induced Hepatic Veno-occlusive Disease. Amer. J. Med. 87:97-99.

Brauchli, J., J. Lüthy et al. 1982. Experientia. 38:1085-87.

Brauchli-Theotokis, J. 1987. Zur Toxikologischen Beurteilung der Pyrrolizidin-Alkaloide in den Arzneipflanzen Symphytum officinale, Borago officinalis. Ph.D. Thesis, University of Zürich, p. 11.

Canada Gazette, 30 March 1988, Part II; Vol. 122, No. 7.

Cheeke, P.R. 1988. Toxicity and Metabolism of Pyrrolizidine Alkaloids. J. Anim. Sci. 66:2342-50.

Clapham, A. R., T. G. Tutin and E. F. Warburg. 1962. Flora of the British Isles. Cambridge, England: Cambridge University Press, p. 654.

Culvenor, C. C. J. 1980. In Toxicology in the Tropics. R. L. Smith, and E. A. Bababumi (eds.). London: Taylor and Francis.

Culvenor, C. C. J. 1987. Personal communication. 24 February 1987.

Culvenor, C. C. J., J. A. Edgar et al. 1980. The Alkaloids of Symphytum x uplandicum (Russian Comfrey). Austr. J. Chem. 33:1105-13.

Furuya, T. and K. Araki. 1968. Studies on Constituents of Crude Drugs I. Alkaloids of Symphytum officinale Linn. Chem. Pharm. Bull. 16:2512-16.

Hills, L. D. 1977. Comfrey: Fodder, Food, and Remedy. New York: Universe Books.

Hirono, I., H. Mori, and M. Haga. 1978. Carcinogenic Activity of Symphytum officinale. J. Nat. Cancer Inst. 61(5): 865-68.

Huizing, H.J., T. W. J. Gadella, and E. Kliphuis. 1982. Chemotaxonomical Investigations of the Symphytum officinale polypoid complex and S. asperum (Boraginaceae): The Pyrrolizidine Alkaloids. Plant Systematics and Evolution. 140: 279-92.

Huxtable, R. J., J. Luthy, and U. Zweifel. 1986. Toxicity of Comfrey-Pepsin Preparations. New England J. Med. 315(17):1095.

Man'ko, I. V., B. K. Kotovskii et al 1970. Level of Alkaloids in Symphytum officinale Dependent on the Phase of Plant Development. Rastit. resur. 6(3):409-11. (as cited in Chem Abstr. 1971. 74:61608).

Mattocks, A. R. 1986. Toxicity of Pyrrolizidine Alkaloids. Nature 217:724.

Mattocks, A. R. 1971. Hepatotoxic Effects Due to Pyrrolizidine Alkaloid N-Oxides. Xenobiotica 1:563-66.

Mattocks, A. R. 1986. Chemistry and Toxicology of Pyrrolizidine Alkaloids. London: Academic Press.

Ridker, P. M., S. Ohkuma, et al. 1985. Hepatic Venoocclusive Disease Associated with the Consumption of Pyrrolizidine-Containing Dietary Supplements. Gastroenterology 88:1050-54.

Roitman, J. N. 1981. Comfrey and Liver Damage. Lancet 1:944.

Roitman, J. N. 1983. In Xenobiotics in Foods and Feeds. J.W. Finely and D.E. Schwass (eds.) Washington, D.C.: American Chemical Society.

Smith, L. W., C. C. J. Culvenor. 1981. The Alkaloids of Symphytum x uplandicum (Russian Comfrey). J. Nat. Prod. 44: 129-52.

Stuart, K. L. and G. Bras. 1957. Veno-occlusive disease of the Liver. Q. J. Med. 26: 291-315.

Vollmer, J. J., N. C. Steiner, et al. 1987. Pyrrolizidine Alkaloids: Testing for Toxic Constituents of Comfrey. J. Chem.Ed. 64(12): 1027-30.

Weston, C. F. M., B. T. Cooper, et al. 1987. Veno-occlusive Disease of the Liver Secondary to Ingestion of Comfrey. Br. Med. J. 295:183.

Würgler, F. E. and E. W. Vogel. 1986. pp. 30-31 In Chemical Mutagens -- Principles and Methods for Their Detection. F. J. de Sorres (ed.) Vol. 10. New York: Plenum Press.

Yeong, M. L., E. Swinbum, et al. 1990. Hepatic Veno-occlusive Disease Associated with Comfrey Ingestion. J. Gastroent. Hepatol. 5:211-14.

Toxicity Footnotes

(1) The most acutely toxic PAs are the macrocyclic diesters of unsaturated necine (aminoalcohol) bases, such as senecionine and monocrotaline. Noncyclic diesters are generally rather less toxic and monoesters notably much less so (Mattocks 1986). However, all esterified 1,2-unsaturated necines ought to be regarded as having the potential for liver damage due to chronic toxicity at surprisingly low levels.

(2) Toxicity of PA is generally regarded as due to hepatic reduction of the 1,2-unsaturated pyrrolizidine structures to highly reactive conjugated dienic pyrroles.

(3) N-oxides are relatively innocuous compared to tertiary bases, undoubtedly because N-oxides are not converted to pyrroles by liver microsomal enzymes in vitro, nor when administered intravenously to rats (Mattocks 1971).

Comfrey: A Clinical Overview

Christiane Staiger*

Comfrey has a centuries-old tradition as a medicinal plant. Today, multiple randomized controlled trials have demonstrated the efficacy and safety of comfrey preparations for the topical treatment of pain, inflammation and swelling of muscles and joints in degenerative arthritis, acute myalgia in the back, sprains, contusions and strains after sports injuries and accidents, also in children aged 3 or 4 and over. This paper provides information on clinical trials and non-interventional studies published on comfrey to date and further literature, substantiating the fact that topical comfrey preparations are a valuable therapy option for the treatment of painful muscle and joint complaints. 

INTRODUCTION

For centuries, comfrey has been used as a traditional medicinal plant for the treatment of painful muscle and joint complaints (Kothmann, 2003; Englert et al., 2005). Commonly found throughout Europe and parts of Asia, the plant also naturalized in North America, where it rapidly spread. Native Americans also recognized its healing powers and included comfrey in their therapeutic armamentarium (Hamel and Chiltoskey, 1975; Stammel, 1986). Comfrey has also been used in veterinary medicine (Rabinovich, 1981).

The German Commission E has assessed preparations containing Symphytum officinale L. positively for the treatment of blunt injuries (Kommission E, 1990a, 1990b). A European Scientific Cooperative on Phytotherapy Monograph is available for comfrey root (Symphyti radix; ESCOP, 2009). In addition, comfrey is described in the Hager Monographs (Staiger, 2009).

The constituents of comfrey root include 0.6–4.7% allantoin (Dennis et al., 1987); abundant mucilage polysaccharides (about 29%) composed of fructose and glucose units (Franz, 1969); phenolic acids such as rosmarinic acid (up to 0.2%), chlorogenic acid (0.012%) as well as caffeic acid (0.004%) and α-hydroxy caffeic acid (Andres, 1991; Grabias and Swiatek, 1998; Teuscher et al., 2009); glycopeptides and amino acids (Hiermann and Writzel, 1998); and triterpene saponins in the form of monodesmosidic and bidesmosidic glycosides based on the aglycones hederagenin (e.g. symphytoxide A), oleanolic acid (Aftab et al., 1996) and lithospermic acid (Wagner et al., 1970).

Comfrey root also consists of pyrrolizidine alkaloids with 1,2-unsaturated necine ring structures, almost entirely in the form of their N-oxides, the main ones being 7-acetylintermedine and 7-acetyllycopsamine together with smaller amounts of intermedine, lycopsamine and symphytine (Brauchli et al., 1982). The total amount of pyrrolizidine alkaloids given by different authors varies from 0.013% to 1.2% based on the analytical methods used (Tittel et al., 1979; Brauchli et al., 1982; Neidhardt, 1982; Stengl et al., 1982; Gracza et al., 1985; Vollmer et al., 1987; Mütterlein and Arnold, 1993).

The pyrrolizidine alkaloids echimidine and symlandine are not found in S. officinale L. and can be used as indicators of possible adulteration with other Symphytum species, such as S. × uplandicum or S. asperum (Mütterlein and Arnold, 1993). Nowadays, only pyrrolizidine-depleted or pyrrolizidine-free extracts are used in proprietary medicinal products. Special cultivars are also used (Schmidt, 2008).

The therapeutic properties of comfrey are based on its antiinflammatory and analgesic effects. Comfrey also stimulates granulation and tissue regeneration, and supports callus formation (Kommission E, 1990a, 1990b). However, the key activity-determining constituents of comfrey extracts and its molecular mechanisms of action have not been completely elucidated. Allantoin and rosmarinic acid are probably of central importance to its pharmacodynamic effects (Andres et al., 1989). No clinical-pharmacokinetic investigation results in humans have been published so far on the absorption, distribution and elimination of the constituents of comfrey extracts.

IN VITRO AND IN VIVO DATA

Rosmarinic acid has been shown to possess antiinflammatory activity in various test systems. It inhibits the formation of malondialdehyde in human platelets (Gracza et al., 1985), prostaglandin synthesis, and carrageenan- and gelatine-induced erythrocyte aggregation (Gracza, 1987). In rat stomach preparations, a glycopeptide isolated from comfrey root dose-dependently inhibited the release of prostaglandins PGE2, PGI2, 12-HETE and arachidonic acid. An orally administered aqueous comfrey root extract inhibited carrageenan-induced rat paw oedema (Hiermann and Writzel, 1998).

In a study of the influence of a 60% ethanolic comfrey root extract on different elements of the human immune system, the extract was found to exert dose-dependent anticomplementary effects on the complement activation (van den Dungen, 1993). Antiinflammatory properties of a dry extract from comfrey root were also demonstrated in rats with induced paw oedema (Shipochliev et al., 1981; Mascolo et al., 1987; Hiermann and Writzel, 1998).

Wound-healing effects have been tested in 40% ethanolic comfrey root extracts and its high molecular weight (MW) fraction (> 1000 kD) in a test model of fibroblasts in a collagen matrix. Both inhibited shrinkage of the collagen matrix (van den Dungen et al., 1990; van den Dungen, 1993).

COMFREY HERB AND LEAVES

Besides the comfrey roots, all the parts of the plant that grow above ground (Symphyti herba) or the leaves (Symphyti folium) are also utilized for medical purposes (Schmidt, 2006). The indications for which randomized clinical trials of ointments containing these kinds of extracts have been conducted include wound healing, myalgia and acute ankle joint distortions.

Wound healing

A topically applied preparation containing 10% active ingredient from the aerial parts of comfrey (Symphytum × uplandicum Nyman, Traumaplant®) was examined for its wound-healing effects (Barna et al., 2007). The randomized, double-blind clinical trial included 278 patients (verum: n = 137) with fresh abrasions. The subjects included 64 patients of up to 20 yr of age (verum n = 29, reference product n = 35). An otherwise identical low-dose preparation (1% active ingredient; n = 141) was used as a reference.

After 2 to 3 days, a significantly and clinically relevantly faster initial reduction in wound size of 49 ± 19% versus 29 ± 13% per day in favour of verum (p < 5 × 10−21) was found. From linear regression time to complete healing was determined to be 2.97 days faster with verum than with the reference (4.08 vs. 7.05 days, p = 7.4 × 10−45 in the t-test comparison of regression lines). The physicians rated efficacy as good to very good in 93.4% of cases, as compared with 61.7% in the group treated with the reference product (p = 2 × 10−11). A subgroup analysis found no significant influence of abrasion area, gender or age on healing effects, albeit that a tendency towards better effects with increasing age was observed. No adverse effects or problems with drug tolerability were observed.

Myalgia

The same topical Symphytum product was tested for its effectiveness and tolerability in the treatment of patients with myalgia (n = 104; Kucera et al., 2005). Again, an otherwise identical low-dose preparation (1% active ingredient; n = 111) was used as a reference. This double-blind, reference-controlled, randomized, multicentre trial included 215 patients with pain in the lower and upper back. The primary efficacy parameter was pain in motion, assessed with the aid of a visual analogue scale. Secondary efficacy parameters included pain at rest, pain on palpation and functional impairment. With high concentrations of the treatment product, amelioration of pain on active motion (p < 5 × 10−9), pain at rest (p < 0.001) and pain on palpation (p = 5 × 10−5) was significantly more pronounced than with the reference product and was clinically highly relevant. A number needed to treat of 3.2 was calculated from the study results. Global efficacy was significantly better (p = 1 × 10−8) and onset of effect was faster (p = 4 × 10−7) with the high-concentration product. Tolerability of the highly concentrated study product was reported good to excellent in all patients.

Distortion

A randomized, multicentre, double-blind study including 203 patients confirmed the efficacy of the same comfrey herb preparation (10% active ingredient of a 2.5:1 aqueous-ethanolic pressed concentrate of freshly harvested, cultivated comfrey herb [Symphytum x uplandicum Nyman], corresponding to 25 g of fresh herb per 100 g of cream) in acute ankle joint distortions, particularly with regard to pain reduction (Kucera et al., 2004). Efficacy and tolerability were compared with a reference product containing 1% of the active ingredient (corresponding to 2.5 g of fresh comfrey herb in 100 g of cream). The reduction of symptom scores for pain when moving, pain at rest and functional restrictions under verum was significant and clinically relevant (p < 0.001) on days 3, 4 and 7. Compared with the reference product, reduction of swelling on days 3 and 4 was equally significant (p < 0.01). One comment on the trial emphasized that using a comparator containing very little of the active ingredient instead of a placebo might be a good approach for clinical trials with herbals, when blinding is difficult (Schulz, 2005a).

OTHER CLINICAL STUDIES AND POST-MARKETING SURVEILLANCE

Several open and post-marketing surveillance studies have also been published. A recent study also included children 4 to 12 yr of age. However, some of the studies are uncontrolled and older than 15 yr.

Children

In an open observational study the above mentioned topical cream was tested in 196 children from the ages of 4 to 12 yr with respect to the paediatric treatment of acute blunt traumata (contusions, strains and distortions; Grünwald et al., 2010). The symptoms pain on palpitation, pain in motion, functional impairment, oedema and haematoma were included in the evaluation. The average duration of the administration of the trial sample was 7.6 ± 1.1 days. The remission rates for the symptoms were 86.3% (pain on palpitation), 86.7% (pain in motion), 89.7% (functional impairment), 94% (oedema), 87.6% (haematoma), and 90.1% (impairment of general condition). No adverse drug reactions occurred.

Muscles and joints

In another open uncontrolled study, the efficacy of the same registered drug containing comfrey herb extract was tested on 105 patients suffering from locomotor system symptoms (Kucera et al., 2000). The cream was applied twice daily. Functional disturbances and pain completely resolved in 57 of the 105 patients. A further 24 patients achieved normalization of function with continued moderately severe pain. Moderate improvement occurred in 21 patients, and three patients reported no improvement in their condition. Muscle pain proved most amenable to treatment with the cream, swelling and overstrain also responded well. The treatment was less efficacious against pain accompanying osteoporosis.

In a study involving 30 patients, the effect of the same preparation was assessed in the treatment of acute supraspinatus tendon syndrome (Mayer, 1993). The ointment was combined in the form of a supplementary percutaneous therapy with local infiltration therapy during the 3-week control period. Compared with the control group, the ointment containing comfrey extracts proved to have a significantly superior effect with regard to the reduction of pain and the associated functional restrictions.

The ointment containing comfrey herb extract was also used to treat 22 additional patients suffering from acute contusions and distortions of the knee joint, and the following clinical symptoms were measured afterwards: swelling of the joint, active and passive pain when moving and local pain when resting (Mayer, 1992). Application of the ointment resulted in a significant alleviation of pain after only 4 days of treatment. All patients were completely pain-free after 10–14 days.

In a 2-week controlled study, the effect of the same ointment was compared with conventional cryotherapy in treating patients with acute ankle joint distortion (Mayer, 1991). Test criteria in this study also included pain at rest, pain when moving and swelling. Symptoms improved significantly quicker during comfrey treatment than during cryotherapy. Application of the ointment containing comfrey proved to be more compliance friendly than cryotherapy.

In another study involving patients with acute contusions and strain traumas of the knee joint, efficacy was proven to be good or even very good and a significant therapeutic impact on the damaged joint became apparent (Hess, 1991). Forty patients suffering from knee joint injuries, sprains and bruises were treated with ointment containing comfrey extract, achieving a significant reduction of pain (pain at rest and on movement) and swelling. The mobility of the affected joint increased significantly. Treatment took place over a period of 8 days and had a good to very good effect on 85% of the patients.

Wounds

A further study examined the effect of an ointment containing Symphytum peregrinum extract in comparison with an active ingredient-free ointment base, i.e. an active ingredient-free polyacrylamide gel, in 10 patients with experimentally produced flat open wounds with the stratum basale intact (Niedner, 1989). The healing time when using ointment containing comfrey extract was significantly shorter than when applying comparative preparations. The difference with regard to the active ingredient-free ointment base was statistically significant.

COMFREY ROOT: RANDOMIZED CLINICAL TRIALS

The medicinal use of preparations from the underground parts of the plants (Symphyti radix) is well established. Relevant medicinal products are now marketed in more than 10 countries and the present licences include the topical treatment of pain, inflammation and swelling of muscles and joints in the case of degenerative arthritis, acute myalgia in the back, sprains, contusions and strains after sports injuries and accidents, also in children aged 3 and over. Corresponding randomized clinical trials and non-interventional studies studied the efficacy of comfrey root extract ointment for treatment of various muscle and joint complaints (Staiger, 2005, 2007).

Back pain

A double-blind, placebo-controlled, multicentre, randomized clinical trial with parallel group design was conducted over a period of 5 days (Giannetti et al., 2010). One-hundred and twenty patients with acute upper or lower back pain were treated three times a day, 4 g per application. They used either a verum cream containing comfrey root fluid extract (1:2, 35.0 g, extraction solvent ethanol 60% (v/v), less than 0.35 ppm of pyrrolizidine alkaloids, Kytta-Salbe®f) or a corresponding placebo. The trial included four visits and was performed at the German Sport University in Cologne (Deutsche Sporthochschule) and three additional ambulatory centres for orthopaedics and sports medicine.

The primary efficacy variable was the area under the curve (AUC) of the Visual Analogue Scale (VAS) on active standardized movement values at visits 1 to 4. The pain intensity on VAS was assessed at performance of standardized, muscle group specific tests. The secondary objectives were back pain at rest using assessment by patient on VAS, pressure algometry (pain–time curve; AUC over 5 days), global assessment of efficacy by the patient and the investigator, intake of analgesic medication and functional impairment measured with the Oswestry Disability Index.

There was a significant treatment difference between comfrey root extract and placebo regarding the primary and secondary variables. The pain intensity on active standardized movement decreased on average (median) approximately 95.2% in the comfrey extract group (104.8–12.7 mm; mean VAS sum) and 37.8% in the placebo group (100.0–56.5 mm; mean VAS sum) (p < 0,001). Compared with placebo, superiority of the verum treatment was significant with regard to secondary efficacy variables (each p < 0.001). Both the AUC of the reported back pain at rest, the AUC of the pressure algometry in the trigger point as well as the global assessment of the efficacy by the patients and the investigators showed a clinically relevant effect in reducing acute back pain. For the first time, a fast-acting effect of the ointment (1 h) was also observed. After 1 h the pain intensity had already decreased about 33.0% in the comfrey group (104.8 to 60.4 mm; mean VAS sum) and 12.0% in the placebo group (100.00 to 86.5; mean VAS sum) indicating an early onset of the treatment effect. A total of seven patients experienced adverse events in the course of the clinical trial, four in the comfrey extract group and three in the placebo group. Eczema, cold, nausea and rhinitis occurred in the verum group, headache (n = 2) and pruritus in the placebo group. All adverse events were of mild severity.

One comment on the trial asked for more data in patients with different sorts of other back pain but admits that the results are relevant and topical treatment is increasingly considered as a serious treatment option (Rannou, 2010).

Painful osteoarthritis

The same cream was investigated in a randomized, double-blind trial including 220 patients suffering from painful osteoarthritis of the knee (Grube et al., 2007). All patients met the criteria of the American College of Rheumatology and received 2 g of either the active or a corresponding placebo cream three times a day for 21 days.

Pain, functional impairment and stiffness are the most important symptoms patients seek to relieve. Therefore, the primary target variable was the VAS sum score of pain at rest and pain on movement. A secondary target variable was the Western Ontario and McMaster Universities (WOMAC) score. During the course of the study, the total score of the primary target variable decreased by 51.6 mm (54.7%) in the verum group and 10.1 mm (10.7%) in the placebo group, a significant difference of 41.5 mm (44.0%) between groups (p < 0.001). The secondary target criterion reduced by 60.4 mm (58.0%) in the verum group and 14.7 mm (14.1%) in the placebo group, the difference of 45.7 mm (43.9%) again being significant (p < 0.001).

Superiority of improvement in the verum group was also evident with respect to four explorative secondary parameters: SF-36 (quality of life), angle measurement (mobility of the knee), CGI (clinical global impression) and global assessment of efficacy by physicians and patients (p < 0.001 for each parameter). A total of 22 AEs occurred in 22 patients (7 in the active therapy group, 15 in the placebo group). No adverse drug reaction was reported in the active therapy group.

One comment on the trial mentioned the difficulties that are usually associated with the production of placebos for herbal drugs. It emphasized that due to the low inherent smell of the extract and the same perfume used in both placebo and verum, a very good blinding could be achieved for this preparation (Schulz, 2007). Another comment found the trial to be well conducted and in accordance with the GCP-ICH guidelines (Chrubasik, 2007).

Blunt injuries

In a double-blind, multicentre, randomized, placebo-controlled, group comparison clinical trial on patients suffering from ankle distortion, the percutaneous efficacy of the same cream of comfrey extract was confirmed decisively (Koll et al., 2000, 2004). The mean age of the 142 patients was 31.8 yr; 78.9% were male. The inclusion criterion was an uncomplicated, acute unilateral ankle distortion that had occurred no longer than 6 h previously. The duration of treatment was 8 days. Local treatment of the afflicted ankle was performed with ca. 2 g (a 6-cm strand of cream) of either verum or placebo.

The primary variable, tenderness of the ankle joint, was measured by pressure algometry, meaning the difference in tolerated pressure between injured and healthy ankles. Under active treatment, no adverse drug reactions were reported. During the course of treatment, pain regressed significantly more in the comfrey extract group than in the placebo group (p < 0.0001) and at the final assessment the reductions in tenderness compared with initial values were 2.44 kp/cm2 in the verum group compared with only 0.95 kp/cm2 in the placebo group. Compared with placebo, superiority of the verum treatment was significant with regard to reduction in pressure pain (tonometric method, p < 0.0001), ankle oedema (figure-of-eight method, p = 0.0001), ankle mobility (dorsiflexion, p = 0.002; plantar flexion, p = 0.0116) and global efficacy (p < 0.0001). A comment valued the trial as a well-executed and designed randomized clinical trial (RCT) with clearly shown beneficial effects (De Lange-de Klerk, 2005).

Verum-controlled versus Diclofenac

In a single-blind, controlled, randomized, parallel groups, multicentre and confirmatory clinical trial outpatients with acute unilateral ankle sprains (n = 164) received either a 6-cm-long ointment layer of the aforementioned comfrey root extract cream (n = 82) or of diclofenac gel containing 1.16 g of diclofenac diethylamine salt (n = 82; Predel et al., 2005). They applied the cream for 7 days, four times a day. The primary efficacy variable was pain arising from pressure on the injured area, measured with a calibrated caliper (algometer) on days 0, 4 and 7 and evaluated by the area under the curve (AUC) of the pain–time curve. Secondary variables were the circumference of the joint (swelling, figure-of-eight method), the individual spontaneous pain sensation at rest and at movement according to a VAS, the global efficacy evaluation, the global assessment of tolerability and further variables. It was confirmatorily shown that comfrey extract is non-inferior to diclofenac. The 95% confidence interval for the AUC (comfrey extract minus diclofenac gel) was 19.08 to 103.09 h*N/cm2 and completely above the margin of non-inferiority. After 7 days of treatment a mean relative reduction in VAS at rest of 92% was found in the comfrey cream group. The corresponding reduction in the diclofenac group was 85%. The mean relative reductions in VAS in motion were 83.2% for comfrey extract and 72.4% for diclofenac. Ankle swelling decreased by 79.5% in the comfrey root and 69.4% in the diclofenac group. The pain on pressure measured with an algometer was reduced by 80.6% in the comfrey root, but only by 74.7% in the diclofenac group.

A re-evaluation of the trial data in accordance with Committee for Proprietary Medicinal Products guidelines (CPMP, 2000) even revealed superiority of the herbal medicine in several parameters (D'Anchise et al., 2007). In the primary variable the comfrey root extract cream showed a statistically significant superiority above the diclofenac gel (p = 0.0012). On day 4, a statistically significant reduction of the pain on pressure (p = 0.0449), and on day 4 (p = 0.0368) and day 7 (p = 0.0074) a statistically significant reduction of the pain on movement was recorded. Further, the physicians (p = 0.0130) as well as the patients (p = 0.0111) rated the global efficacy of the comfrey preparation significantly higher than the efficacy of the diclofenac gel.

Comments on the trial appreciated the proof of efficacy compared with the chemical comparator (Schulz, 2005b) and referred to the observer-blind design as the best possible in cases where a double-blind design cannot be performed (Chrubasik, 2006).

Other clinical trials

In an earlier 4-week pilot study, 41 patients with different forms of musculoskeletal rheumatism (mainly epicondylitis, tendovaginitis and periarthritis) were treated topically with the same cream as above (n = 20) or with placebo (n = 21) (Petersen et al., 1993). Efficacy was assessed using several pain parameters: tenderness when pressure applied, pain at rest and during exercise. With respect to ‘tenderness when pressure applied’, the ointment proved superior to placebo in patients with epicondylitis and tendovaginitis, but not in patients with periarthritis.

The effects of dermatological preparations containing 5% or 10% of a comfrey root extract (2:7, 50% ethanol) on the process of healing of experimentally induced UV-B erythema were studied in 29 volunteers in a controlled pharmacological trial (Andres et al., 1989; Andres, 1991). The antiinflammatory potency of the extract was found to be equal to or greater than that of diclofenac. A positive correlation could be demonstrated between efficacy and the concentration of α-hydroxy caffeic acid in the extract, but not for allantoin.

POST-MARKETING SURVEILLANCE

The results of the non-interventional studies are in line with the results of the aforementioned clinical trials. In particular, data for children aged 3 to 12 yr is available.

Children

In a non-interventional study of a comfrey root extract cream containing 35% of a comfrey root extract (1:2, ethanol 60% (v/v)) the tolerability and efficacy were examined in 306 children aged 3 to 12 yr (Staiger and Wegener, 2008). The preparation was used to treat a variety of conditions such as contusions (61.4%), strains (14.1%), distortions (30.4%) and other indications (6.9%). The ointment was applied to most of the children three times daily (57.8%), four times daily (26.1%) or twice a day (13.4%). Thereby the physicians administered mostly the same dosages as for adults and children aged 12 yr and older. In the overall score of the findings pain on palpation, restriction of movement and haematoma manifestation (minimum 3, maximum 15) a notable improvement in the clinical result became clear: the initial value of 10.61 fell by 6.18 points or by 58.3%. Clear remission or improvement was revealed in every individual finding. For all clinical symptoms, an improvement of over 50% could be calculated. The most marked reduction was in pain at rest (62.6%), restriction of movement (62.0%) and pain sensitivity (61.4%).

Comfrey cream

In a post-marketing surveillance study, 163 patients with a mean age of 45.3 yr applied the same comfrey root extract cream for several conditions, the most frequent being contusions (33.1%), painful joint complaints (27.6%), sprains (26.4%) and painful muscle complaints (23.3%; Tschaikin, 2004). Most patients applied the preparation two (38%) or three (48.5%) times daily. The median duration of treatment was 11.5 days. During the observation period symptoms of pain at rest and during the night, pain during motion, tenderness when pressure applied, impaired mobility, painful muscle complaints and swellings improved markedly. Morning joint stiffness decreased by 94% from 17 min initially to 1 min. The use of non-steroidal antiinflammatory drugs (NSAIDs) was reduced or discontinued by 13.5% of patients. The physicians assessed global efficacy as excellent in 38.7% of cases and good in 54.6%.

Comfrey paste

In a simultaneous surveillance study, 162 patients applied a similar preparation, a paste containing 30% of the above mentioned fluid extract of comfrey roots (Pabst and Ottersbach, 2004). They also treated a variety of conditions such as painful joint complaints (34%), contusions (26.5%) or painful muscle complaints (21.6%). Most patients applied the preparation once (23.5%) or twice (52.5%) daily. The median duration of treatment was 11.8 days. Again, symptoms of pain at rest and pain during movement, impaired mobility, swelling and painful muscle complaints improved markedly during the observation period. Morning stiffness of investigated joints decreased by 90% from 20 min initially to 2 min. The use of NSAIDs was reduced or discontinued by 21% of patients. Global efficacy was assessed by the physicians as excellent in 65.4% of cases and good in 32.7%.

Combination with methyl nicotinate

A cream consisting of a combination of 35% of comfrey root fluid extract and 1.2 % methyl nicotinate is available in Germany, Luxembourg and Switzerland. A further simultaneous non-interventional study of this preparation included 162 patients (Klingenburg, 2004). The mean age of the patients was 49.7 yr, the mean duration of treatment 12.3 days. Pain at rest and during the night was reduced by 45%, pain during motion by 47%, tenderness when pressure applied by 47%, painful muscle complaints by 48%, and impaired mobility improved by 46%. In the course of the study, four patients with seven non-serious, resolved adverse events, namely skin reactions such as redness or itching, were recorded.

Other data

A total data analysis of the previous three post-marketing surveillance studies is also available (Koll and Klingenburg, 2002). The findings are in line with the aforementioned results. With regard to all 492 patients, pain at rest, pain in movement, and tenderness when pressure applied improved, decreasing by 45–47% on average.

The effects of dermatological preparations containing 5% or 10% of a comfrey root extract (2:7, 50% ethanol) on the process of healing of experimentally induced UV-B erythema were studied in 29 volunteers in a controlled trial. The antiinflammatory potency of the extract was found to be equal to or greater than that of diclofenac. A positive correlation could be demonstrated between efficacy and the concentration of a caffeic acid derivative in the extract, but not for allantoin (Andres et al., 1989; Andres, 1991).

Comfrey root has also been used for knee joint injuries and non-active gonarthrosis, as well as in the treatment of tendinitis syndrome, insect bites, mastitis, fractures, skin inflammation, multiple abscesses of sweat glands, gangrenous ecthymas, furuncles, dicubital ulcers and chronic varicose ulceration, as prior studies and individual case reports reflect (Häberle, 1952; Briel, 1953; Ziolkowski et al., 1957; Korte and Rapp, 1958; Büzberger, 1960; Prinzing, 1960; Deister, 1963; Awang, 1987; Koehler and Franz, 1987; Kothmann, 2003; Barnes et al., 2007).

SAFETY

With regard to safety, the absence of genotoxic effects was demonstrated in the bacterial reverse mutation assay (Ames test) for a pyrrolizidine alkaloids (PA)-free comfrey root liquid extract (Benedek et al., 2010). The extract was investigated for its ability to induce gene mutations in Salmonella typhimurium strains TA 98, TA 100, TA 102, TA 1535 and TA 1537 with and without metabolic activation using the mammalian microsomal fraction S9 mix. Reference mutagens were used to check the validity of the experiments. The comfrey root extract showed no biologically relevant increases in revertant colony numbers of any of the five tester strains, neither in the presence nor in the absence of metabolic activation. In conclusion, the fluid extract was not mutagenic in the bacterial reverse mutation assay.

Literature on comfrey often concentrates on PAs, recommending a restriction of the duration of treatment, also with externally applied comfrey preparations. However, in Germany, the restriction limiting application to 4–6 weeks/yr applies only to preparations containing more than 10 µg, but less than 100 µg pyrrolizidine alkaloids (daily allowance; Bundesgesundheitsamt, 1992). Fully licenced medicinal products available today contain depleted or PA-free extracts. The application results in far below the daily allowance of 10 µg. As a consequence there are no restrictions in Germany on these products as regards the duration of treatment (Bundesgesundheitsamt, 1992).

DISCUSSION

Comfrey has a long tradition as a medicinal plant. In general, the effects of comfrey extracts can be described as pain relieving, antiinflammatory and callus formation promoting. To date, the activity-determining constituents and mechanisms of action of the medicinal plant are only partly known. However, in accordance with the modern approach of evidence-based medicine, comfrey extract creams have demonstrated their efficacy and tolerability in a number of muscle and joint injuries, such as acute myalgia in the back area, and in blunt injuries. Comfrey herb has also been shown to be efficacious in wound healing. Comfrey root has also proven to be efficacious in activated osteoarthritis, and equivalent or more efficacious in distortions compared with topical diclofenac. Although for each indication and licenced product only one modern randomized clinical trial is available so far, they all point to the pain-relieving effect in muscle and joint complaints. It could therefore be promising to investigate topical comfrey preparations in further indications related to muscle or joint pain, for instance chronic forms of back pain.

CONCLUSION

In the 17th century, Nicholas Culpeper (1616–1654) mentioned comfrey in his enlarged version of The English Physitian (Culpeper, 1656). He stated: ‘It is said to be so powerful to consolidate and knit together (…) and a Syrup made thereof is very effectual for all those (…) outward Wounds and Sores in the Fleshy or Sinewy part of the Body whatsoever’. He recommended comfrey among many other complaints for ‘Inward Wounds & Bruises, Wounds, Ruptures, broken Bones, Inflamation, Gout, and Pained Joynts.’

Today, this historical statement is widely supported by modern clinical data. Several recent randomized clinical trials substantiate the efficacy of topical comfrey preparations in the treatment of pain, inflammation and swelling of muscles and joints in the case of degenerative arthritis, acute myalgia in the back, sprains, contusions and strains after sports injuries and accidents, also in children aged 3 and over.

LITERATUUR

1. Aftab K, Shaheen F, Mohammad FV, Noorwala M, Ahmad VU. Phyto-pharmacology of saponins from Symphytum officinale L. Adv Exp Med Biol. 1996;404:429–442. [PubMed] [Google Scholar]

2. Andres RMP. 1991. Klinische und instrumentalanalytische Untersuchung von Dermatika mit Extrakten aus Symphytum officinale L. Dissertation, University of Bern.

3. Andres P, Brenneisen R, Clerc JT. Relating antiphlogistic efficacy of dermatics containing extracts of Symphytum officinale to chemical profiles. Planta Med. 1989;55:66–67. [Google Scholar]

4. Awang DVC. Comfrey. Can Pharm J. 1987;120:101–104. [Google Scholar]

5. Barna M, Kucera A, Hladícova M, Kucera M. Der wundheilende Effekt einer Symphytum-Herba-Extrakt-Creme (Symphytum × uplandicum Nyman): Ergebnisse einer randomisierten, kontrollierten Doppelblindstudie. Wien Med Wochenschr. 2007;157:569–574. [PubMed] [Google Scholar]

6. Barnes J, Anderson LA, Phillipson JD. Herbal Medicines. 3rd edn. London: Pharmaceutical Press; 2007. Comfrey; pp. 188–190. [Google Scholar]

7. Benedek B, Ziegler A, Ottersbach P. Absense of mutagenic effects of a particular Symphytum officinale L. liquid extract in the bacterial reverse mutation assay. Phytother Res. 2010;24:466–468. [PubMed] [Google Scholar]

8. Brauchli J, Lüthy J, Zweifel U, Schlatter CH. Pyrrolizidine alkaloids from Symphytum officinale L. and their percutaneous absorption in rats. Experientia. 1982;38:1085–1087. [PubMed] [Google Scholar]

9. Briel R. Die Anwendung von Symphytum officinale, einer natürlichen Cholin-Allantoin-Kombination in der Gynäkologie. Med Klin. 1953;19:676–678. [PubMed] [Google Scholar]

10. Bundesgesundheitsamt. 1992. Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln (Abwehr von Arzneimittelrisiken – Stufe II). Vom 5, Bundesanzeiger No. 111: 4805.

11. Büzberger M. Poliklinische Anwendung von Kytta Plasma und Kytta Salbe. Med Welt. 1960;27/28:1499–1500. [PubMed] [Google Scholar]

12. Chrubasik S. Comparison of local Symphytum officinale L. (comfrey) root extract and diclofenac for sprained ankles. Focus Altern Complement Ther. 2006;11:21–22. [Google Scholar]

13. Chrubasik S. Effectiveness of Symphytum officinale (comfrey root) extract ointment in painful knee osteoarthritis. Focus Altern Complement Ther. 2007;12:177–178. [Google Scholar]

14. CPMP. 2000. Points to Consider on Switching Between Superiority and Non-inferiority. Committee for Proprietary Medicinal Products, EWP/482/99.

15. Culpeper N. The English Physitian enlarged: With Three Hundred, Sixty, and Nine Medicines, made of English Herbs that are not in any Impression until this: The Epistle will inform you how to know This impression from any other. Being an Astrologo-Physical Discourse of the Vulgar Herbs of this Nation. Containing a Compleat Method or Physick, whereby a man may preserve his Body in health; or Cure himself, being Sick, for three pence Charge, with such things only as grow in England, they being most fit for English Bodies. London: Peter Cole; 1656. [Google Scholar]

16. D'Anchise R, Bulitta M, Giannetti B. Comfrey extract ointment in comparison to a diclofenac gel in the treatment of acute unilateral ankle sprains (distortions) Arzneim-Forsch Drug Res. 2007;57:712–716. [PubMed] [Google Scholar]

17. De Lange-de Klerk ESM. Symphytum officinale (comfrey) ointment relieves pain and swelling after ankle distortion. Focus Altern Complement Ther. 2005;10:24–25. [Google Scholar]

18. Deister J. Über die Anwendung von Symphytum officinale – Präparaten in der Chirurgie. Landarzt. 1963;39:297–298. [Google Scholar]

19. Dennis R, Dezelak C, Grime J. Studies on Symphytum species – HPLC determination of allantoin. Acta Pharm Hung. 1987;57:267–274. [PubMed] [Google Scholar]

20. Englert K, Mayer JG, Staiger C. Symphytum officinale L. Der ‘Beinwell’ in der europäischen Pharmazie- und Medizingeschichte. Z Phytother. 2005;26:158–168. [Google Scholar]

21. ESCOP. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd edn. Stuttgart: European Scientific Cooperative on Phytotherapy, Thieme Verlag; 2009. Symphyti radix, Comfrey root; pp. 249–254. Supplment 2009. [Google Scholar]

22. Franz G. Untersuchungen über die Schleimpolysaccharide von Tussilago farfara L., Symphytum officinalis L., Borago officinalis L. und Viola tricolor L. Planta Med. 1969;17:217–220. [PubMed] [Google Scholar]

23. Giannetti BM, Staiger C, Bulitta M, Predel HG. Efficacy and safety of a comfrey root extract ointment in the treatment of acute upper or lower back pain: results of a double-blind, randomised, placebo controlled, multicentre trial. Br J Sport Med. 2010;44:637–641. [PubMed] [Google Scholar]

24. Grabias B, Swiatek L. Phenolic acids in Symphytum officinale L. Pharm Pharmacol Lett. 1998;8:81–83. [Google Scholar]

25. Gracza L. Prüfung der membranabdichtenden Wirkung eines Phytopharmakons und dessen Wirkstoffe. Z Phytother. 1987;8:78–81. [Google Scholar]

26. Gracza L, Koch H, Löffler E. Isolierung von Rosmarinsäure aus Symphytum officinale und ihre anti-inflammatorische Wirksamkeit in einem In-vitro-Modell. Über biochemisch-pharmakologische Untersuchungen pflanzlicher Arzneistoffe, 1. Mitt. Arch Pharm. 1985;318:1090–1095. [PubMed] [Google Scholar]

27. Grube B, Grünwald J, Krug L, Staiger C. Efficacy of a comfrey root (Symphyti offic. radix) extract ointment in the treatment of patients with painful osteoarthritis of the knee: Results of a double-blind, randomised, bicenter, placebo-controlled trial. Phytomedicine. 2007;14:2–10. [PubMed] [Google Scholar]

28. Grünwald J, Bitterlich N, Nauert C, Schmidt M. Anwendung und Verträglichkeit von Beinwellcreme (Symphyti herba) bei Kindern mit akuten stumpfen Traumen. Z Phytother. 2010;31:61–65. [Google Scholar]

29. Häberle A. Erfahrungen mit dem Präparat Kytta-Plasma. Der Krankenhausarzt. 1952;25:22–23. [Google Scholar]

30. Hamel PB, Chiltoskey MU. Cherokee Plants. Their uses – a 400 year history. Sylva, NC: Herald Publishers; 1975. [Google Scholar]

31. Hess H. Wirkung einer Symphytum-Salbe bei Sportverletzungen des Kniegelenks. Dtsch Z Sportmed. 1991;42:156–162. [Google Scholar]

32. Hiermann A, Writzel M. Antiphlogistic glycopeptide from the roots of Symphytum officinale. Pharm Pharmacol Lett. 1998;8:154–157. [Google Scholar]

33. Klingenburg S. Wärmendes Topikum mit Symphytum officinale. Erfahrungsheilkunde. 2004;53:350–354. [Google Scholar]

34. Koehler H, Franz G. Symphytum officinale – Beinwell. Z Phytother. 1987;8:166–168. [Google Scholar]

35. Koll R, Klingenburg S. Therapeutische Eigenschaften und Verträglichkeit topischer Beinwellzubereitungen bei Prellungen, Zerrungen, Verstauchungen sowie bei schmerzhaften Muskel- und Gelenkbeschwerden: Ergebnisse einer Beobachtungsstudie an Patienten. Fortschr Med. 2002;120:1–9. [PubMed] [Google Scholar]

36. Koll R, Buhr M, Dieter R, et al. Wirksamkeit und Verträglichkeit von Beinwellwurzelextrakt (Extr. Rad. Symphyti) bei Sprunggelenksdistorsionen. Ergebnisse einer multizentrischen, randomisierten, placebo-kontrollierten Doppelblindstudie. Z Phytother. 2000;21:127–134. [Google Scholar]

37. Koll R, Buhr M, Dieter R, et al. Efficacy and tolerance of a comfrey root extract (Extr. Rad. Symphyti) in the treatment of ankle distortions: results of a multicenter, randomized, placebo-controlled, double-blind study. Phytomedicine. 2004;11:470–477. [PubMed] [Google Scholar]

38. Kommission E. 1990a. Monographie Symphyti herba/-folium (Beinwellkraut/-blätter). Bundesanzeiger, 318.

39. Kommission E. 1990b. Monographie Symphyti radix (Beinwellwurzel). Bundesanzeiger, 318.

40. Korte H, Rapp G. Erfahrungsbericht über die Anwendung von Kytta-Salbe und Kytta-Plasma in der Ambulanz unserer Klinik. Med Klin. 1958;25:1104–1105. [PubMed] [Google Scholar]

41. Kothmann H. Beinwell – Wirkungsgeschichte und Bedeutungswandel einer Heilpflanze. Hamburg: Verlag Dr. Kovac; 2003. [Google Scholar]

42. Kucera M, Kalal J, Polesna Z. Effects of Symphytum ointment on muscular symptoms and functional locomotor disturbances. Adv Ther. 2000;17:204–210. [PubMed] [Google Scholar]

43. Kucera M, Barna M, Horácek O, Kováriková J, Kucera A. Efficacy and safety of topical applied Symphytum herb extract cream in the treatment of ankle distorsion: Results of a randomized controlled clinical double-blind study. Wien Med Wochenschr. 2004;154:498–507. [PubMed] [Google Scholar]

44. Kucera M, Barna M, Horácek O, Kálal J, Kucera A, Hladícova M. Topical symphytum herb concentrate cream against myalgia. A randomized controlled double blind clinical study. Adv Ther. 2005;22:681–692. [PubMed] [Google Scholar]

45. Mascolo N, Autore G, Capasso F, Menghini A, Fasulo MP. Biological screening of Italian medicinal plants for anti-inflammatory activity. Phytother Res. 1987;1:28–31. [Google Scholar]

46. Mayer G. Die Lokalbehandlung der akuten lateralen Distorsion des oberen Sprunggelenkes mit einer Symphytum-Wirkstoffkomplex-Salbe. Acta Ther. 1991;17:89–100. [Google Scholar]

47. Mayer G. Die Lokalbehandlung von Kontusionen und Distorsionen des Kniegelenkes mit einer Symphytum-Wirkstoffkomplex-Salbe. Erfahrungsheilkunde. 1992;12:888–891. [Google Scholar]

48. Mayer G. Die Lokalbehandlung des akuten Supraspinatussehnen-Syndroms mit einer Symphytum-Wirkstoffkomplex-Salbe. Dtsch Z Sportmed. 1993;44:121–124. [Google Scholar]

49. Mütterlein R, Arnold CG. Untersuchungen zum Pyrrolizidinalkaloidgehalt und Pyrrolizidinalkaloidmuster in Symphytum officinale L. Versuche zur Gewinnung pyrrolizidinalkaloidarmer Pflanzen bzw. Pflanzenteile. Pharm Ztg Wiss. 1993;138:119–125. [Google Scholar]

50. Neidhardt U. 1982. HPLC-Analytik der Pyrrolizidin-Alkaloide von Symphytum Drogen. Dissertation, University of München.

51. Niedner R. Beeinflussung der Epithelialisierung durch einen Wirkstoffkomplex aus Symphytum. Acta Ther. 1989;15:289–297. [Google Scholar]

52. Pabst H, Ottersbach P. Topikum bei Muskel- und Gelenkbeschwerden. Geriatr J. 2004;6(6):45–47. [Google Scholar]

53. Petersen G, Lorkowski G, Kasper FR, Gottwald R, Lücker PW. Anti-inflammatory activity of a pyrrolizidine alkaloid-free extract of roots of Symphytum officinale in humans. Planta Med. 1993;59(Suppl):A703–A704. [Google Scholar]

54. Predel HG, Giannetti B, Koll R, Bulitta M, Staiger C. Efficacy of a comfrey root extract ointment in comparison to a diclofenac gel in treatment of ankle distortions: results of an observer-blind, randomized, multicenter study. Phytomedicine. 2005;12:707–714. [PubMed] [Google Scholar]

55. Prinzing G. Symphytum in der Praxis. Fortschr Med. 1960;78:225–256. [Google Scholar]

56. Rabinovich MI. Medicinal Plants in the Veterinary Medicine. Moscow: Russagricultural Publishing House; 1981. pp. 49–50. [Google Scholar]

57. Rannou F. Is Symphytum officinale (comfrey) root extract ointment useful in the treatment of back pain? Focus Altern Complement Ther. 2010;15:119–120. [Google Scholar]

58. Schmidt M. Beinwellsalbe bei stumpfen Traumen und Muskelschmerzen. Erfahrungsheilkunde. 2006;55:326–329. [Google Scholar]

59. Schmidt M. Hochleistungssort, ‘Harras’ als Beitrag zu Qualität, Wirksamkeit und Sicherheit von Beinwell (Symphytum x uplandicum Nyman) Z Arznei- Gewürzpflanzen. 2008;13:182–184. [Google Scholar]

60. Schulz V. Beinwell-Creme lindert akute Beschwerden nach Sprungelenksdistorsion. Doppelblindstudie bei 203 Patienten belegt signifikante Behandlungserfolge. Z Phytother. 2005a;26:222–223. [Google Scholar]

61. Schulz V. Beinwell-Salbe bei akuter Sprunggelenksdistorsion wirkäquivalent mit Diclofenac. Z Phytother. 2005b;26:278–279. [Google Scholar]

62. Schulz V. Wirksamkeit einer Beinwell-Salbe im Vergleich mit Placebo bei 220 Patienten mit Osteoarthritis des Kniegelenkes. Z Phytother. 2007;28:125–126. [Google Scholar]

63. Shipochliev T, Dimitrov A, Aleksandrova E. Study on the anti-inflammatory effect of a group of plant extracts [Russian/English summary] Vet Med Nauki (Sofia) 1981;18:87–94. [PubMed] [Google Scholar]

64. Staiger C. Beinwell – eine moderne Arzneipflanze. Z Phytother. 2005;26:169–173. [Google Scholar]

65. Staiger C. Beinwell – Stand der klinischen Forschung. Z Phytother. 2007;28:110–114. [Google Scholar]

66. Staiger C. Symphytum. In: Blaschek W, Ebel S, Hackenthal E, et al., editors. HagerROM 2009: Hagers Enzyklopädie der Arzneistoffe und Drogen. Berlin: Springer-Verlag; 2009. [Google Scholar]

67. Staiger C, Wegener T. Beinwell in der Therapie stumpfer Traumen: Anwendung bei Kindern. Z Phytother. 2008;29:58–63. [Google Scholar]

68. Stammel HJ. Die Apotheke Manitous. Das medizinische Wissen der Indianer und ihre Heilpflanzen. Reinbeck: Wunderlich-Verlag; 1986. pp. 242–245. 147, 160, 175, 204. [Google Scholar]

69. Stengl P, Wiedenfeld H, Roeder E. Pyrrolizidine alkaloids: testing for toxic constituents of comfrey. Dtsch Apoth Ztg. 1982;122:851–855. [Google Scholar]

70. Teuscher E, Willuhn G, Loew D. Symphyti radix – Beinwellwurzel. In: Wichtl M, editor. Teedrogen und Phytopharmaka. Ein Handbuch für die Praxis auf wissenschaftlicher Grundlage. 5th edn. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2009. pp. 644–646. [Google Scholar]

71. Tittel G, Hinz H, Wagner H. Quantitative determination of pyrrolizidine alkaloids in Symphyti Radix by HPLC. Planta Med. 1979;37:1–8. [Google Scholar]

72. Tschaikin M. Extrakt aus Symphytum officinale Wirksamkeit und Verträglichkeit bei topischer Anwendung. Naturheilpraxis. 2004;57:576–578. [Google Scholar]

73. Van den Dungen FM. 1993. Symphytum officinale L. Influence on immune functions and wound-healing processes. Dissertation Universiteit: Utrecht.

74. Van den Dungen FM, Fischer FC, Souren JEM, Labadie RP. The effect of some Symphytum officinale tincture fractions on the shrinking of a collagen matrix by fibroblasts. Pharm Weekbl Sci Ed. 1990;12(Suppl A):A15. [Google Scholar]

75. Vollmer J, Steiner N, Larsen G, Muirhead K, Molyneux R. Pyrrolizidine alkaloids: testing for toxic constituents of comfrey. J Chem Educ. 1987;64:1027–1030. [Google Scholar]

76. Wagner H, Hörhammer L, Frank U. Lithospermsäure, das antihormonale Wirkprinzip von Lycopus europaeus L. (Wolfsfuß) und Symphytum officinale L. (Beinwell). 3. Mitteilung: Über die Inhaltsstoffe von Arzneipflanzen mit hormon- und antihormonähnlicher Wirkung. Arzneim-Forsch Drug Res. 1970;20:705–713. [PubMed] [Google Scholar]

77. Ziolkowski Z, Orszulak J, Wojtanowska H. Aqueous extract of Symphytum officinale in the treatment of some skin diseases in infants. Pediatr Pol. 1957;32:1353–1360. [PubMed] [Google Scholar]

Smeerwortelolie en zalf

Smeerwortel wordt vooral gebruikt bij wondbehandeling en huidaandoeningen. De allantoïne en silicium in de plant spelen een grote rol in weefselherstel. Het is erg effectief bij kneuzingen, blauwe plekken, rugpijn, spierpijn, littekens, botbreuken en reumatische aandoeningen. Gebruik het alleen op open wonden als de wond goed ontsmet is. Smeerwortel laat de wond immers zeer snel dichtgroeien, waardoor een infectie ingekapseld kan worden. Naast dit uitwendige gebruik kan de plant ook inwendig ingezet worden bij luchtwegklachten en infecties aan de spijsverteringsorganen, vanwege de verzachtende slijmstoffen in de plant.

Inwendig gebruik van Smeerwortel zou ik niet aanraden. Smeerwortel bevat immers pyrrolizidine alkaloïden (PA’s). Deze plantenstoffen zijn niet afbreekbaar in de lever en kunnen zich daar opstapelen en op termijn leveraandoeningen zoals levercirrose of zelfs leverkanker veroorzaken. PA’s zijn chemisch gezien wateroplosbare stoffen. Dat betekent dat je ze terugvindt als je er een kruidenthee of tinctuur van maakt. Smeerwortelthee is daarom geen goed idee. De bladeren worden soms ook culinair gebruikt – want ze zijn erg lekker – maar het is vanwege de hoeveelheid PA’s niet verstandig om vaak te eten. 

PA’s lossen niet goed op in vetten, dus als je er een kruidenolie van maakt, zitten ze er nauwelijks in. Deze kruidenolie kan je vervolgens gebruiken om een fijne, zeer effectieve zalf te maken tegen blauwe plekken, kneuzingen, spierpijn, reumatische aandoeningen en wonden. Het onderstaande recept voor smeerwortelzalf is zeer effectief tegen blauwe plekken, kneuzingen, spierpijn, reumatische aandoeningen en is ook geschikt als wondzalf. En Smeerwortelzalf zelf maken is niet moeilijk!

Smeerwortelzalf

• 1 potje van 30 ml

• 50 g sesamolie (kan ook met olijfolie of kokosolie)

• Een paar bladeren van de Gewone Smeerwortel (of stukjes van de wortel, bij voorkeur niet tijdens de bloei uitgraven)

• 5 g bijenwas of 4 g candelillawas (vegan)

• Optioneel: 5 druppels Lavendel of Helicryse etherische olie

Pluk een paar verse bladeren van de Gewone Smeerwortel. Snijd ze in kleine stukken en stop ze in een glazen pot (vb. een jampot) samen met de sesamolie. Duw de bladeren goed onder de olie. Verwarm de pot ongeveer 48 uur au bain-marie op 40-50°C. Zeef vervolgens de bladeren uit de olie met een fijne zeef en filter het na door een koffiefilter. Dit gaat heel langzaam, dus geef de olie de tijd om er rustig doorheen te druppelen. De olie heeft een prachtige, diep donkergroene kleur. Als de olie gezeefd en gefilterd is, weeg je er 30 g van af met een keukenweegschaal. Verwarm dit samen met de was au bain-marie, tot de was gesmolten is. Dit is ongeveer bij 65°C (het smeltpunt van candelillawas is iets hoger). Laat de substantie afkoelen tot rond de 40°C. Voeg een paar druppels etherische olie toe en roer het goed door het mengsel heen. Giet het mengsel snel in een zalfpotje en laat het opstijven.

De smeerwortelzalf alleen uitwendig gebruiken! Je kunt de zalf drie maal daags dun op de blauwe plek of de wond aanbrengen. Smeer de smeerwortelzalf niet op open wonden. 

Lavendel en Helicrysum zijn beide etherische oliën die ingezet worden bij blauwe plekken, wonden en huidaandoeningen. Helicrysum (Helichrysum italicum), ook wel Kerrieplant genoemd, is fantastisch in een zalf tegen blauwe plekken, maar is nogal duur en soms moeilijk te vinden. Lavendel is dan een goed alternatief